Citadel Advisors
AEMD icon

Citadel Advisors’s Aethlon Medical AEMD Stock Holding History

Citadel Advisors’s Portfolio AEMD Stock Details AEMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-38
Closed -$116K – 13708
2021
Q3 		$116K Buy
+38
New +$128K ﹤0.01% 12684

Other funds holding AEMD

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Citadel Advisors's AEMD Position: Q4 2025 in Review

Citadel Advisors sold out of Aethlon Medical (AEMD) in Q4 2025, closing a stake of 9,508 shares — an estimated $71.2K sold.

Citadel Advisors first reported a position in AEMD in Q3 2017 and held it in 10 quarters. The position peaked at $72K in Q3 2022. 8 funds tracked by Wall St. Rank hold AEMD as of Q4 2025.

  • Citadel Advisors reported no remaining Aethlon Medical position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 9,508 Aethlon Medical shares in Q4 2025, an estimated $71.2K.
  • Citadel Advisors first reported a position in Aethlon Medical in Q3 2017 and held it in 10 quarters.
  • Citadel Advisors's Aethlon Medical position peaked at $72K in Q3 2022.
  • 8 funds tracked by Wall St. Rank held Aethlon Medical as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.